Jeffrey S. Mathiesen

Chief Financial Officer

US·SEC (Form 4)

Helius Medical Technologies, Inc.Panbela Therapeutics, Inc.NEUROONE MEDICAL TECHNOLOGIES Corp

Total declarations

Companies

▲ Purchases (1 ops.)

€14k

▼ Sales (0 ops.)

—

Latest filing published 07 Apr 2026 for NEUROONE MEDICAL TECHNOLOGIES Corp. Read the official filing

Filing timeline

BuySale

Jeffrey S. Mathiesen

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

T+90 mean return

-21.6%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

No signal scores available.

Jeffrey S. Mathiesen: trading record in brief

This profile gathers the share dealings of Jeffrey S. Mathiesen across 3 companies, led by NEUROONE MEDICAL TECHNOLOGIES Corp, Solana Co and Panbela Therapeutics, Inc. Between 25 May 2021 and 3 April 2026, the trades on record add up to 9 filings.

The open-market record is one-sided, with 1 purchase worth €14k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 8 share grants.

The record was last updated on 7 April 2026 with a share grant in NEUROONE MEDICAL TECHNOLOGIES Corp. The most recent open-market purchase was published on 20 December 2021, 1,763 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.